Cargando…

SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer

Recurrent inactivating mutations in components of SWI/SNF chromatin-remodeling complexes have been identified across cancer types, supporting their roles as tumor suppressors in modulating oncogenic signaling pathways. We report here that SMARCE1 loss induces EGFR expression and confers resistance t...

Descripción completa

Detalles Bibliográficos
Autores principales: Papadakis, Andreas I, Sun, Chong, Knijnenburg, Theo A, Xue, Yibo, Grernrum, Wipawadee, Hölzel, Michael, Nijkamp, Wouter, Wessels, Lodewyk FA, Beijersbergen, Roderick L, Bernards, Rene, Huang, Sidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387553/
https://www.ncbi.nlm.nih.gov/pubmed/25656847
http://dx.doi.org/10.1038/cr.2015.16
Descripción
Sumario:Recurrent inactivating mutations in components of SWI/SNF chromatin-remodeling complexes have been identified across cancer types, supporting their roles as tumor suppressors in modulating oncogenic signaling pathways. We report here that SMARCE1 loss induces EGFR expression and confers resistance to MET and ALK inhibitors in non-small cell lung cancers (NSCLCs). We found that SMARCE1 binds to regulatory regions of the EGFR locus and suppresses EGFR transcription in part through regulating expression of Polycomb Repressive Complex component CBX2. Addition of the EGFR inhibitor gefitinib restores the sensitivity of SMARCE1-knockdown cells to MET and ALK inhibitors in NSCLCs. Our findings link SMARCE1 to EGFR oncogenic signaling and suggest targeted treatment options for SMARCE1-deficient tumors.